Xilio director granted 5,000 stock options

Xilio Therapeutics director Daniel J. Curran received a grant of stock options covering 5,000 shares of common stock.

Rhea-AI Filing Summary

Xilio Therapeutics director Daniel J. Curran received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $7.99 per share and bring his total option holdings reported in this filing to 5,000 derivative shares.

The award was granted as of June 11, 2026 and will vest as to 100% of the underlying shares on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders following the grant date, provided he continues to serve the company through the vesting date. This is a compensation-related grant rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 5,000 shares

Grant/Award 1 txn

Insider Curran Daniel J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	5,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 5,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Key Figures

Options granted: 5,000 shares Exercise price: $7.99 per share Total options after grant: 5,000 shares +2 more

5 metrics

Options granted 5,000 shares Stock Option (right to buy) grant on June 11, 2026

Exercise price $7.99 per share Conversion or exercise price for granted options

Total options after grant 5,000 shares Total derivative shares following transaction

Option expiration June 10, 2036 Expiration date of stock option grant

Vesting condition 100% by earlier of June 11, 2027 or next annual meeting Subject to continued service through vesting date

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 7.9900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option was granted on June 11, 2026 and will vest as to 100% of the shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders following the grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Xilio Therapeutics (XLO) director Daniel Curran report in this Form 4?

Director Daniel J. Curran reported a grant of stock options for 5,000 shares of Xilio Therapeutics common stock at an exercise price of $7.99 per share, reflecting a compensation-related equity award.

How many Xilio Therapeutics (XLO) options were granted to Daniel Curran?

Daniel J. Curran received stock options covering 5,000 shares of Xilio Therapeutics common stock. Following this grant, his reported derivative holdings in this filing total 5,000 option shares tied to this award.

What is the exercise price of Daniel Curran’s Xilio Therapeutics (XLO) stock options?

The granted stock options have an exercise price of $7.99 per share. This is the price at which Curran may purchase Xilio Therapeutics common shares once the options vest and are exercisable.

When do Daniel Curran’s Xilio Therapeutics (XLO) options vest?

The options will vest as to 100% of the underlying 5,000 shares on the earlier of June 11, 2027 or Xilio Therapeutics’ next annual stockholders’ meeting after the grant, assuming his continued service through vesting.

Is Daniel Curran’s Xilio Therapeutics (XLO) Form 4 an open-market trade?

No. The Form 4 reflects a grant/award acquisition of stock options as compensation, not an open-market purchase or sale. The transaction code is “A,” indicating a grant or award by the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Curran Daniel J.

(Last) (First) (Middle)

828 WINTER STREET

SUITE 300

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xilio Therapeutics, Inc. [ XLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.99	06/11/2026		A		5,000		(1)	06/10/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Christopher Frankenfield, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)